Clinical Trial

A Phase I Study of SSGJ-612 in Patients With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 25, 2025 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is an open-label phase I study to evaluate the safety, pharmacokinetics, and antitumor activity of SSGJ-612 in patients with advanced malignant solid tumors expressing HER2.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-19.
Status change: Not Yet Recruiting → Recruiting 2025-07-22
Trial Details
NCT Number NCT07032298
Lead Sponsor Shenyang Sunshine Pharmaceutical Co., LTD.
Conditions Advanced Malignant Tumors
Enrollment 30 participants
Start Date 2025-07-18
Primary Completion 2026-04 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2025-07-25